Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

10X Genomics Inc (TXG)

10X Genomics Inc (TXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,356,417
  • Shares Outstanding, K 126,553
  • Annual Sales, $ 642,820 K
  • Annual Income, $ -43,540 K
  • EBIT $ -41 M
  • EBITDA $ -151 M
  • 60-Month Beta 2.24
  • Price/Sales 3.57
  • Price/Cash Flow N/A
  • Price/Book 2.92

Options Overview Details

View History
  • Implied Volatility 75.81% (-4.91%)
  • Historical Volatility 62.46%
  • IV Percentile 28%
  • IV Rank 32.50%
  • IV High 127.16% on 04/23/25
  • IV Low 51.09% on 08/21/25
  • Expected Move (DTE 1) 0.96 (4.91%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 1,043
  • Volume Avg (30-Day) 528
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 10,513
  • Open Int (30-Day) 9,344
  • Expected Range 18.61 to 20.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.25
  • Number of Estimates 8
  • High Estimate -0.07
  • Low Estimate -0.41
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +30.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.26 +13.38%
on 02/12/26
23.56 -16.94%
on 01/23/26
-0.95 (-4.63%)
since 01/16/26
3-Month
15.18 +28.92%
on 12/15/25
23.56 -16.94%
on 01/23/26
+4.01 (+25.77%)
since 11/18/25
52-Week
6.78 +188.64%
on 04/07/25
23.56 -16.94%
on 01/23/26
+7.50 (+62.14%)
since 02/18/25

Most Recent Stories

More News
3 Volatile Stocks We Steer Clear Of

3 Volatile Stocks We Steer Clear Of

TXG : 19.57 (+5.10%)
ASLE : 7.39 (+0.41%)
WFC : 88.56 (+1.33%)
Why Is 10x Genomics (TXG) Stock Soaring Today

Why Is 10x Genomics (TXG) Stock Soaring Today

TXG : 19.57 (+5.10%)
TXG Q4 Deep Dive: Consumables Growth, Spatial Expansion, and AI-Driven Demand Shape Outlook

TXG Q4 Deep Dive: Consumables Growth, Spatial Expansion, and AI-Driven Demand Shape Outlook

TXG : 19.57 (+5.10%)
10x Genomics (NASDAQ:TXG) Delivers Impressive Q4 CY2025

10x Genomics (NASDAQ:TXG) Delivers Impressive Q4 CY2025

TXG : 19.57 (+5.10%)
10x Genomics: Q4 Earnings Snapshot

10x Genomics: Q4 Earnings Snapshot

TXG : 19.57 (+5.10%)
10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026

PLEASANTON, Calif. , Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full...

TXG : 19.57 (+5.10%)
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect

10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect

TXG : 19.57 (+5.10%)
PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology

Initiative will create one of the world's largest multimodal cancer datasets and an integrated suite of AI models and tools to fuel precision medicine

TXG : 19.57 (+5.10%)
1 Momentum Stock to Target This Week and 2 We Turn Down

1 Momentum Stock to Target This Week and 2 We Turn Down

SITE : 152.39 (-0.74%)
TXG : 19.57 (+5.10%)
NIC : 153.50 (-2.65%)
Cathie Wood Just Bet $26 Million on Broadcom Stock. Should You Buy AVGO Too?

Cathie Wood bets on Broadcom while shorting major market names in a week of activity.

BLSH : 31.85 (-0.47%)
ARKX : 32.25 (+1.99%)
NFLX : 77.99 (+1.29%)
META : 643.22 (+0.61%)
ROKU : 90.21 (+1.84%)
TXG : 19.57 (+5.10%)
GTLB : 28.98 (+1.97%)
AVGO : 333.51 (+0.29%)
TWST : 54.92 (+3.86%)
ILMN : 120.09 (+3.07%)
CRCL : 63.15 (+2.48%)
WRD : 7.37 (-4.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

10x Genomics Inc. is a life science technology company. It develops and sells instruments, consumables and software for analyzing biological systems. 10x Genomics Inc. is based in Pleasanton, California.

See More

Key Turning Points

3rd Resistance Point 21.37
2nd Resistance Point 20.58
1st Resistance Point 20.07
Last Price 19.57
1st Support Level 18.77
2nd Support Level 17.98
3rd Support Level 17.47

See More

52-Week High 23.56
Last Price 19.57
Fibonacci 61.8% 17.15
Fibonacci 50% 15.17
Fibonacci 38.2% 13.19
52-Week Low 6.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar